Breakthrough breast cancer drug
The word "remarkable" isn't often used to describe breast cancer treatments, but that's what doctors are calling T-DM1. It's a new drug for an especially ferocious cancer that accounts for 20% of breast cancers and affects women of all ages. "It's a remarkable drug for two reasons. One, it's very effective even in women who've already had their cancer progress on prior therapies. And two, it's remarkably low in side effects," says Dr. Ian Krop, assistant professor of medicine at Harvard Medical School and one of the lead investigators in the third and most recent trial of the drug. Findings were presented in June at the annual meeting of the American Society of Clinical Oncology.
To continue reading this article, you must log in.
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.
- Research health conditions
- Check your symptoms
- Prepare for a doctor's visit or test
- Find the best treatments and procedures for you
- Explore options for better nutrition and exercise
I'd like to receive access to Harvard Health Online for only $4.99 a month.
Sign Me UpAlready a member? Login ».
Disclaimer:
As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles.
No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.
